Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 3Thoracic 1Lymphoid 1Head & Neck 1Genitourinary 1Dermatologic 1CNS 1

Conditions

Ureteral Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Neoplasm Metastasis 1Melanoma 1Lung Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Carboplatin 510Cisplatin 410Pemetrexed 400Radiotherapy 285Docetaxel 244Paclitaxel 227pembrolizumab 226Gemcitabine 198Drug Therapy 191Bevacizumab 190Erlotinib Hydrochloride 189Radiosurgery 177Nivolumab 168Etoposide 155durvalumab 154osimertinib 126atezolizumab 109Gefitinib 96Blood Specimen Collection 93Magnetic Resonance Spectroscopy 91Vinorelbine 90anlotinib 88Surgical Procedures, Operative 85Ipilimumab 62Immunotherapy 62Surveys and Questionnaires 60sintilimab 59Specimen Handling 59tislelizumab 58Irinotecan 57

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × abexinostat × Thoracic × Clear all
NCT03590054 2024-03-22

Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies

University of California, San Francisco

Phase 1 Completed
35 enrolled
DermatologicGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Ureteral Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡